- Conditions
- Schizophrenia
- Interventions
- SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Irving, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Placebo, Standard of Care
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
- Conditions
- Negative Symptoms of Schizophrenia
- Interventions
- Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
- Drug
- Lead sponsor
- Minerva Neurosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Psychosis, Anxiety, Depression, Rumination
- Interventions
- Smartphone-based Mindfulness Exercise, Smartphone-based Psychoeducation, Neutral Control Message
- Behavioral
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Schizophrenia
- Interventions
- CBSST-CCT, Goal focused supportive contact
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Tocilizumab, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia
- Interventions
- Study App
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia
- Interventions
- Transcranial Direct Current Stimulation
- Device
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Schizophrenia
- Interventions
- D-serine
- Drug
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders
- Interventions
- risperidone, sertraline-primary
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia
- Interventions
- Placebo, Bitopertin, Antipsychotics
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 27
- States / cities
- Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
- Conditions
- Schizophrenia
- Interventions
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
- Conditions
- Schizoaffective Disorder, Schizophrenia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 4,914 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
- Device
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
- Interventions
- N-acetylcysteine, Treatment as Usual
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Schizophrenia
- Interventions
- CT-155, Digital Control
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 54
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 50 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, bitopertin [RO4917838]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 21
- States / cities
- Carson, California • Oceanside, California • San Diego, California + 17 more
- Conditions
- Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
- Interventions
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Device
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- d-cycloserine, glycine, placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
- Conditions
- Schizophrenia
- Interventions
- 1 Hz rTMS, 10 Hz rTMS
- Device
- Lead sponsor
- Seton Healthcare Family
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Interventions
- Dipyridamole, Olanzapine
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia
- Interventions
- Oral Glucose Tolerance Test (OGTT)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- RO6889450, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 28
- States / cities
- Bellflower, California • Garden Grove, California • Glendale, California + 23 more